Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

39.63 +0.10 (+0.25%)

Delayed Quote Updated: 3:20 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited Ordinary Shares

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

35 36 Next >

Li Auto Posts Q4 Earnings, Joins Teva Pharmaceutical And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

February 26, 2024

U.S. stock futures were lower this morning, with the Dow futures trading lower by over 50 points on Monday.

Via Benzinga

Topics Stocks

Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China

February 26, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

6 reasons to buy Teva Pharmaceuticals stock sooner than later

February 26, 2024

Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why

Via MarketBeat

Topics Lawsuit

Beyond The Numbers: 8 Analysts Discuss Teva Pharmaceutical Indus Stock ↗

February 12, 2024

Via Benzinga

A Preview Of Teva Pharmaceutical Indus's Earnings ↗

January 30, 2024

Via Benzinga

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

February 23, 2024

From Alvotech

Via GlobeNewswire

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

February 23, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential ↗

February 22, 2024

MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.

Via Talk Markets

Teva Pharma CEO Dismisses Split Speculations Expects Significant Interest For Its API Business Divestiture: Report ↗

February 20, 2024

Teva Pharmaceutical Industries confirms unity and dispels split rumors. CEO Richard Francis emphasizes the synergy between generics and branded drugs.

Via Benzinga

Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting

February 20, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise ↗

February 12, 2024

Shares of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) climbed in early trading on Monday, after several analysts raised their forecasts.

Via Benzinga

CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday ↗

February 12, 2024

U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading.

Via Benzinga

Topics Stocks

Teva Pharmaceutical To Rally Around 58%? Here Are 10 Top Analyst Forecasts For Monday ↗

February 12, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

3 Biotech Stocks to Buy for the Next Bull Run: February 2024 ↗

February 08, 2024

These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month.

Via InvestorPlace

Teva Pharmaceutical Industries (TEVA) Q4 2023 Earnings Call Transcript ↗

January 31, 2024

TEVA earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On Wednesday ↗

January 31, 2024

U.S. stocks traded mostly lower, with the Nasdaq Composite falling over 200 points on Wednesday.

Via Benzinga

Topics Stocks

Generic Drug Player Teva Pharma To Divest Its Active Pharmaceutical Ingredient Business, Q4 Earnings Surpass Estimates ↗

January 31, 2024

Teva Pharmaceutical surpasses Q4 2023 sales expectations, reporting $4.46 billion. Teva plans to divest API business for revenue optimization. Outlook for FY 2024.

Via Benzinga

Teva Sinks On Lackluster Profit Outlook Despite Walloping Quarterly Projections ↗

January 31, 2024

Teva Pharmaceutical easily beat fourth-quarter views, but its 2024 profit guidance left something to be desired.

Via Investor's Business Daily

Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser ↗

January 31, 2024

The record run of the market faces risk as the big tech earnings season got off to a negative start, casting cloud on profit outlook.

Via Benzinga

Topics Economy

Teva Reports Growth in Fourth Quarter and Full Year 2023

January 31, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy

January 31, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

Stocks Mixed Ahead Of Big Tech Earnings ↗

January 30, 2024

Stocks are a mixed bag this afternoon, following the start of the Federal Reserve's two-day policy meeting.

Via Talk Markets

Topics Economy

Enphase Energy To Rally Over 35%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

January 23, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Earnings Scheduled For January 31, 2024 ↗

January 31, 2024

Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion.

Via Benzinga

Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? ↗

January 29, 2024

An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.

Via Benzinga

Topics Artificial Intelligence

In-Depth Examination Of 4 Analyst Recommendations For Teva Pharmaceutical Indus ↗

January 23, 2024

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

January 22, 2024

Via Benzinga

Healthcare Giant Eli Lilly Under FDA Lens Again For Manufacturing Lapses ↗

January 19, 2024

Eli Lilly faces FDA scrutiny with eight deficiencies at its Branchburg plant, raising concerns on Emgality's manufacturing.

Via Benzinga

Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space ↗

January 12, 2024

The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease.

Via Investor's Business Daily

3 No-Brainer Stocks to Buy With $20 Right Now ↗

January 10, 2024

You don't need a mountain of cash to begin building your wealth on Wall Street.

Via The Motley Fool

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.